Search research articles
Contact Us
Filters
Showing results (31-40 of 102) with videos related to
Page
of 11
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 8, 2012
Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis
Beth Woods, Neil Hawkins, William Dunlop, et al.
Plos One
|
March 14, 2012
An economic evaluation of preclinical testing strategies compared to the compulsory scrapie flock scheme in the control of classical scrapie
Lisa Boden, Ian Handel, Neil Hawkins, et al.
Pharmaceutical Statistics
|
June 17, 2014
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Christine Fletcher, Christy Chuang-Stein, Marie-Ange Paget, et al.
BMC Women'S Health
|
March 16, 2024
The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis
Dana M Chase, Anadi Mahajan, David Alexander Scott, et al.
BMC Public Health
|
March 22, 2018
A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries
Cameron M Wright, Lydia Boudarène, Ninh Thi Ha, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 15, 2021
Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data
Edit Remák, Neil Hawkins, Trefor Jones, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 29, 2023
Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
Dana M Chase, Anadi Mahajan, David Alexander Scott, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum
Antonia Morga, Nicholas R Latimer, Martin Scott, et al.
Journal of Comparative Effectiveness Research
|
June 9, 2022
Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome
Neil Hawkins, Noemi Muszbek, Rachel Evans, et al.
Pharmacoeconomics
|
November 8, 2017
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment
Jaclyn Beca, Don Husereau, Kelvin K W Chan, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 102) with videos related to
Sort By:
Page
of 11
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 8, 2012
Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis
Beth Woods, Neil Hawkins, William Dunlop, et al.
Plos One
|
March 14, 2012
An economic evaluation of preclinical testing strategies compared to the compulsory scrapie flock scheme in the control of classical scrapie
Lisa Boden, Ian Handel, Neil Hawkins, et al.
Pharmaceutical Statistics
|
June 17, 2014
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Christine Fletcher, Christy Chuang-Stein, Marie-Ange Paget, et al.
BMC Women'S Health
|
March 16, 2024
The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis
Dana M Chase, Anadi Mahajan, David Alexander Scott, et al.
BMC Public Health
|
March 22, 2018
A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries
Cameron M Wright, Lydia Boudarène, Ninh Thi Ha, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 15, 2021
Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data
Edit Remák, Neil Hawkins, Trefor Jones, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 29, 2023
Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
Dana M Chase, Anadi Mahajan, David Alexander Scott, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum
Antonia Morga, Nicholas R Latimer, Martin Scott, et al.
Journal of Comparative Effectiveness Research
|
June 9, 2022
Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome
Neil Hawkins, Noemi Muszbek, Rachel Evans, et al.
Pharmacoeconomics
|
November 8, 2017
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment
Jaclyn Beca, Don Husereau, Kelvin K W Chan, et al.
Page
of 11